WMSA
CASC

Weiss Multi-Strategy Advisers’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Weiss Multi-Strategy Advisers’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-3,933
Closed -$76K – 807
2014
Q2 		$76K Sell
3,933
-234
-6% -$4.13K ﹤0.01% 704
2014
Q1 		$75K Buy
+4,167
New +$68.4K ﹤0.01% 940
2013
Q4 		– Sell
-8,333
Closed -$103K – 1191
2013
Q3 		$103K Buy
+8,333
New +$87.7K ﹤0.01% 886

Other funds holding CASC

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Weiss Multi-Strategy Advisers's CASC Position: Q2 2015 in Review

Weiss Multi-Strategy Advisers sold out of Cascadian Therapeutics, Inc. (CASC) in Q2 2015, closing a stake of 35,583 shares — an estimated $348K sold.

Weiss Multi-Strategy Advisers first reported a position in CASC in Q3 2013 and held it in 7 quarters. The position peaked at $437K in Q4 2014. 100 funds tracked by Wall St. Rank hold CASC as of Q2 2015.

  • Weiss Multi-Strategy Advisers reported no remaining Cascadian Therapeutics, Inc. position as of Q2 2015 after selling out during the quarter.
  • Weiss Multi-Strategy Advisers sold 35,583 Cascadian Therapeutics, Inc. shares in Q2 2015, an estimated $348K.
  • Weiss Multi-Strategy Advisers first reported a position in Cascadian Therapeutics, Inc. in Q3 2013 and held it in 7 quarters.
  • Weiss Multi-Strategy Advisers's Cascadian Therapeutics, Inc. position peaked at $437K in Q4 2014.
  • 100 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q2 2015.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q2 2015, filed 14 Aug 2015.